Literature DB >> 21890513

S-carboxymethylcysteine inhibits adherence of Streptococcus pneumoniae to human alveolar epithelial cells.

Tomoko Sumitomo1, Masanobu Nakata1, Masaya Yamaguchi2, Yutaka Terao1, Shigetada Kawabata1.   

Abstract

Streptococcus pneumoniae is a major pathogen of respiratory infections that utilizes platelet-activating factor receptor (PAFR) for firm adherence to host cells. The mucolytic agent S-carboxymethylcysteine (S-CMC) has been shown to exert inhibitory effects against infection by several respiratory pathogens including S. pneumoniae in vitro and in vivo. Moreover, clinical studies have implicated the benefits of S-CMC in preventing exacerbation of chronic obstructive pulmonary disease, which is considered to be related to respiratory infections. In this study, to assess whether the potency of S-CMC is attributable to inhibition of pneumococcal adherence to host cells, an alveolar epithelial cell line stimulated with interleukin-1α was used as a model of inflamed epithelial cells. Despite upregulation of PAFR by inflammatory activation, treatment with S-CMC efficiently inhibited pneumococcal adherence to host epithelial cells. In order to gain insight into the inhibitory mechanism, the effects of S-CMC on PAFR expression were also investigated. Following treatment with S-CMC, PAFR expression was reduced at both mRNA and post-transcriptional levels. Interestingly, S-CMC was also effective in inhibiting pneumococcal adherence to cells transfected with PAFR small interfering RNAs. These results indicate S-CMC as a probable inhibitor targeting numerous epithelial receptors that interact with S. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890513     DOI: 10.1099/jmm.0.033688-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  8 in total

1.  Pneumococcal BgaA Promotes Host Organ Bleeding and Coagulation in a Mouse Sepsis Model.

Authors:  Moe Takemura; Masaya Yamaguchi; Momoko Kobayashi; Tomoko Sumitomo; Yujiro Hirose; Daisuke Okuzaki; Masayuki Ono; Daisuke Motooka; Kana Goto; Masanobu Nakata; Narikazu Uzawa; Shigetada Kawabata
Journal:  Front Cell Infect Microbiol       Date:  2022-07-01       Impact factor: 6.073

Review 2.  A review on anti-adhesion therapies of bacterial diseases.

Authors:  Arezoo Asadi; Shabnam Razavi; Malihe Talebi; Mehrdad Gholami
Journal:  Infection       Date:  2018-10-01       Impact factor: 3.553

3.  Capsaicin inhibitory effects on Vibrio cholerae toxin genes expression.

Authors:  Soroor Erfanimanesh; Gita Eslami; Arezou Taherpour; Ali Hashemi
Journal:  Avicenna J Phytomed       Date:  2019 May-Jun

Review 4.  Clinical Efficacy of Carbocysteine in COPD: Beyond the Mucolytic Action.

Authors:  Elisabetta Pace; Isa Cerveri; Donato Lacedonia; Gregorino Paone; Alessandro Sanduzzi Zamparelli; Rossella Sorbo; Marcello Allegretti; Luigi Lanata; Francesco Scaglione
Journal:  Pharmaceutics       Date:  2022-06-14       Impact factor: 6.525

5.  GP96 Drives Exacerbation of Secondary Bacterial Pneumonia following Influenza A Virus Infection.

Authors:  Tomoko Sumitomo; Masanobu Nakata; Satoshi Nagase; Yuki Takahara; Mariko Honda-Ogawa; Yasushi Mori; Yukako Akamatsu; Masaya Yamaguchi; Shigefumi Okamoto; Shigetada Kawabata
Journal:  mBio       Date:  2021-06-01       Impact factor: 7.867

6.  Sinefungin, a natural nucleoside analogue of S-adenosylmethionine, inhibits Streptococcus pneumoniae biofilm growth.

Authors:  Mukesh Kumar Yadav; Seok-Won Park; Sung-Won Chae; Jae-Jun Song
Journal:  Biomed Res Int       Date:  2014-06-23       Impact factor: 3.411

7.  Shin'iseihaito (Xinyiqingfeitang) Suppresses the Biofilm Formation of Streptococcus pneumoniae In Vitro.

Authors:  Masaaki Minami; Toru Konishi; Hiroshi Takase; Toshiaki Makino
Journal:  Biomed Res Int       Date:  2017-04-16       Impact factor: 3.411

Review 8.  Respiratory Barrier as a Safeguard and Regulator of Defense Against Influenza A Virus and Streptococcus pneumoniae.

Authors:  Kim S LeMessurier; Meenakshi Tiwary; Nicholas P Morin; Amali E Samarasinghe
Journal:  Front Immunol       Date:  2020-02-04       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.